Home › beta-Thalassemia › NCT06271512
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry)
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Participant must be treated with beti-cel in the post marketing setting at a center in the US that participates in the Registry. * Participant must sign an informed consent and/or assent prior to enrollment as required under applicable laws and regulations. * Participant must have signed an informed consent and/or assent permitting data to be shared with Center for International Blood and Marrow Transplant Research (CIBMTR). * Participant must be followed by a hematologist based in the US. Exclusion Criteria: \- There are no exclusion criteria for Registry participation.
About the study
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
What is being tested
- No Intervention (other)
Sponsor: Genetix Biotherapeutics Inc. · Participants: 150 · Started: Jan 23, 2024
Contact the study team
- bluebird bio · Phone: +1-833-999-6378
Official record on ClinicalTrials.gov — NCT06271512
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.